Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues:
Total revenue	$ 4,282,586	$ 5,435,444
Operating expenses:
General and administrative	2,573,311	3,382,070
Research and development	1,420,985	3,567,263
Sales and marketing	1,076,527	0
Royalty Expense	934,005	313,668
Total operating expenses	6,004,828	7,263,001
Loss from operations	(1,722,242)	(1,827,557)
Other income (expense):
Interest income, net	76,599	121,695
Loss on foreign exchange	0	(30,158)
Total other income (expense)	76,599	91,537
Loss before provision for income taxes	(1,645,643)	(1,736,020)
Income tax expense	(39,000)	0
Net loss	(1,684,643)	(1,736,020)
Other comprehensive loss:
Foreign currency translation adjustment	(293,491)	0
Comprehensive loss	$ (1,978,134)	$ (1,736,020)
Net loss per share of common stock:
Basic and Diluted (in dollars per share)	$ (0.40)	$ (0.44)
Weighted average shares outstanding used to compute net loss per share:
Basic and Diluted (in shares)	4,224,555	3,909,702
Royalty and licensing revenue
Revenues:
Total revenue	$ 4,198,500	$ 3,746,250
Treatment investment revenue
Revenues:
Total revenue	0	80,495
Grant and contract revenue
Revenues:
Total revenue	$ 84,086	$ 1,608,699